The Cystic Fibrosis Foundation mourns the passing of long-standing CF community champion and philanthropic leader who helped to raise more than $500 million toward the CF cause.
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.
Jan. 5, 2024
|
2 min read